2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. ADC Antibody

ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.

ADC Antibody Related Products (123):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99238
    Rolinsatamab
    Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C).
    Rolinsatamab
  • HY-P9988
    Mecbotamab
    		99.83%
    Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011).
    Mecbotamab
  • HY-P9980A
    Belantamab (FUT8-KO)
    		98.10%
    Belantamab (FUT8-KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT8-KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin.
    Belantamab (FUT8-KO)
  • HY-P99712
    Lonigutamab
    Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases.
    Lonigutamab
  • HY-P991080
    Anti-SLC44A4 Antibody
    		≥99.0%
    Anti-SLC44A4 Antibody (ASG-5ME Antibody) is a SLC44A4 targeting antibody that can be used for synthesis of ADC ASG-5ME.
    Anti-SLC44A4 Antibody
  • HY-P991723
    Varsetatug
    Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer.
    Varsetatug
  • HY-P99656
    Iladatuzumab
    Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.
    Iladatuzumab
  • HY-P99506
    Tamrintamab
    		98.51%
    Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research.
    Tamrintamab
  • HY-P991359
    Anti-FOLH1/PSMA Antibody (J591)
    Anti-FOLH1/PSMA Antibody (J591) (MEDI3726 antibody) is a human monoclonal antibody (mAb) targeting FOLH1/PSMA. Anti-FOLH1/PSMA Antibody (J591) can be used in Prostate cancer research.
    Anti-FOLH1/PSMA Antibody (J591)
  • HY-P991238
    MEDI4276 Antibody
    MEDI4276 Antibody is an HER2-targeted antibody, which can be used for the synthesis of the ADC molecule MEDI4276. MEDI4276 Antibody can be used in the study of cancer.
    MEDI4276 Antibody
  • HY-P991662
    AMG-595 Antibody
    AMG-595 Antibody is a EGFRvIII targeting antibody. AMG-595 Antibody can be used for synthesis of ADC AMG-595.
    AMG-595 Antibody
  • HY-P99045A
    Sacituzumab (powder)
    		98.33%
    Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer.
    Sacituzumab (powder)
  • HY-P991995
    OMTX005
    		98.44%
    OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC50: 0.33 nM)/mouse (EC50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research.
    OMTX005
  • HY-P990786
    Anti-FLT3 Antibody (AGS62P)
    Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3, and can be used for acute myelogenous leukemia.
    Anti-FLT3 Antibody (AGS62P)
  • HY-P991742
    LY4101174 Antibody
    		99.46%
    LY4101174 Antibody is an ADC antibody. LY4101174 is an antibody-drug conjugate (ADC) that targets the nectin-4 protein present on the surface of certain cancer cells. It can directly deliver a potent chemotherapy agent (Exatecan (HY-13631)) to the tumor site and is used for the study of advanced cancers, such as urothelial carcinoma, triple-negative breast cancer, and non-small cell lung cancer.
    LY4101174 Antibody
  • HY-P99225A
    Mirvetuximab (powder)
    		99.31%
    Mirvetuximab (M9346A) (powder) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab (powder) is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research.
    Mirvetuximab (powder)
  • HY-P99733
    Mipasetamab
    		98.26%
    Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity.
    Mipasetamab
  • HY-P991699
    Lixarkitug
    		99%
    Lixarkitug (AZD9829 antibody; INT-020) is a humanized IgG1κ antibody targeting IL-3Ra/CD123. Lixarkitug can be conjugated with Samrotecan to form the intact ADC molecule lixarkitug samrotecan (AZD9829), which is used in studies of acute myeloid leukemia (AML). The isotype control corresponding to Lixarkitug is Human IgG1 kappa, Isotype Control (HY-P99001).
    Lixarkitug
  • HY-P991505
    Anti-HER3 Antibody (Ab562)
    		99.63%
    Anti-HER3 Antibody (Ab562) is an anti-HER3 monoclonal antibody. Anti-HER3 Antibody (Ab562) can be used to synthesize the antibody-drug conjugate (ADC) AMT-562 (HY-171747).
    Anti-HER3 Antibody (Ab562)
  • HY-P99487
    Briobacept
    Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA).
    Briobacept